Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.17 USD
-0.10 (-7.87%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ADAP 1.17 -0.10(-7.87%)
Will ADAP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADAP
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ADAP
Adaptimmune price target lowered by 50c at JonesResearch, here's why
Agilent gets FDA approval for Tecelra companion diagnostic
Buy Rating Affirmed for Adaptimmune on TECELRA’s Market Potential and FDA Approval
Adaptimmune’s TECELRA®: FDA Approval Marks Solid Tumor Breakthrough
Adaptimmune granted FDA accelerated nod for lead asset